ELOX · XBRL financial data

Eloxx Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ELOX's year ends in late December)

In thousands of dollars	FY 2018Dec 31, 2018	FY 2019Dec 31, 2019	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2025Dec 31, 2025
Revenue	—	—	—	—	—	0
Research and development	20,489	25,842	14,590	—	—	—
General and administrative	26,482	24,713	14,847	20,449	10,692	3,382
Total operating expenses	47,565	50,555	33,455	66,018	34,419	6,438
Operating income (loss)	(47,565)	(50,555)	(33,455)	(66,018)	(34,419)	(6,438)
Other income (expense)	502	(319)	(1,122)	(709)	(1,646)	443
Income tax expense (benefit)	122	0	0	0	0	0
Net income (loss)	(47,185)	(50,874)	(34,577)	(66,727)	(36,065)	(5,995)
Earnings per share, basic USD per share	—	—	—	(38.15)	(16.65)	(0.49)
Earnings per share, diluted USD per share	—	—	—	(38.15)	(16.65)	(0.49)
Weighted average shares, basic thousands of shares	—	—	—	1,749	2,166	12,347
Weighted average shares, diluted thousands of shares	—	—	—	1,749	2,166	12,347

† Share count changed about 1/40 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (ELOX's year ends in late December)

In thousands of dollars	FY 2018Dec 31, 2018	FY 2019Dec 31, 2019	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2025Dec 31, 2025
Cash and cash equivalents	48,606	22,493	24,668	42,268	19,207	4,785
Marketable securities	—	33,783	—	—	—	—
Prepaid and other current assets	1,690	1,390	1,169	913	661	479
Total current assets	50,341	57,709	25,893	43,480	20,129	5,270
Property and equipment, net	248	201	133	216	169	0
Right-of-use asset	—	924	421	1,443	825	0
Total assets	50,718	58,947	26,477	45,139	21,123	5,270
Accounts payable	747	1,871	481	1,379	3,020	2,713
Accrued liabilities	6,938	4,655	2,886	4,196	2,799	1,613
Current portion of long-term debt	—	4,336	5,239	0	3,980	1,000
Total current liabilities	7,807	11,807	9,838	9,955	23,091	17,177
Long-term debt	—	10,502	6,376	11,996	8,557	0
Lease liability, non-current	—	425	33	804	135	0
Total liabilities	7,807	22,734	16,247	22,755	31,783	17,177
Accumulated deficit	(86,145)	(137,019)	(171,596)	(238,323)	(274,388)	(300,580)
Total stockholders' equity	42,911	36,213	10,230	22,384	(10,660)	(11,907)
Total liabilities and equity	50,718	58,947	26,477	45,139	21,123	5,270
Common shares outstanding (cover page) thousands of shares	35,860	40,118	40,215	86,653	2,166	5,072

† Share count changed about 1/40 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (ELOX's year ends in late December)

In thousands of dollars	FY 2018Dec 31, 2018	FY 2019Dec 31, 2019	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2025Dec 31, 2025
Net income (loss)	(47,185)	(50,874)	(34,577)	(66,727)	(36,065)	(5,995)
Stock-based compensation	13,370	11,336	8,666	9,167	3,021	235
Net cash from operating activities	(31,367)	(39,391)	(28,166)	(35,001)	(31,845)	(6,327)
Purchases of property and equipment	235	40	—	89	66	—
Net cash from investing activities	(317)	(33,524)	33,792	2,056	(66)	1
Proceeds from issuing common stock	2,165	710	—	47,718	0	0
Dividends paid	0	0	—	—	—	—
Proceeds from long-term debt	—	15,000	797	11,874	0	2,865
Net cash from financing activities	56,184	46,800	(3,438)	50,788	8,812	11,001
Net change in cash	24,500	(26,115)	2,188	17,843	(23,099)	4,675

† Share count changed about 1/40 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Eloxx Pharmaceuticals	61,960	not reported	(4,789)*	4.0M	12.9 quarters	Q2 FY26 10-QJun 30, 2026
NovAccess Global	21	0*	(55)*	61.7M	0.4 quarters	Q4 FY24 10-KSep 30, 2024
Bioadaptives	29	5	(44)*	196.9M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
CNBX Pharmaceuticals	9.5	0	(48)*	1.6B	0.2 quarters	Q3 FY26 10-QMay 31, 2026
Avenue Therapeutics	1,942	0	(475)*	3.3M	4.1 quarters	Q2 FY26 10-QJun 30, 2026
Emmaus Life Sciences	2,808	6,318	1,693*	70.2M	—	Q2 FY26 10-QJun 30, 2026
International Stem Cell	1,089	2,675	167*	8.0M	—	Q2 FY26 10-QJun 30, 2026
Nutra Pharma	not reported	34	(251)*	7.2B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Mosaic ImmunoEngineering	0	not reported	(0)*	7.2M	0.6 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.